{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:26:30Z","timestamp":1791476790053,"version":"4.3.4"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"\n Importance<\/jats:title>\n The benefit of adjuvant chemotherapy (ACT) following curative resection of colorectal liver metastases (CRLM) remains uncertain, with no consistent overall survival (OS) benefit and optimal patient selection for postsurgical treatment not established.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between circulating tumor DNA (ctDNA)\u2013defined molecular residual disease (MRD) and survival outcomes and whether MRD status is associated with differential benefit from ACT in resected CRLM.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective analysis included patients with resected CRLM enrolled in the CIRCULATE-Japan GALAXY study between May 2020 and July 2024 with available ctDNA results 2 to 10 weeks after surgery. Analyses were landmarked at 70 days and conducted separately for patients receiving neoadjuvant chemotherapy (NAC) and those undergoing upfront surgery. Data were analyzed from January to April 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Postsurgical ACT vs observation. ctDNA was assessed using a personalized, tumor-informed assay.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Disease-free survival (DFS) and OS, evaluated using Cox proportional hazards models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 298 included patients, the median (range) age was 67 (33-85) years, and 192 (64.4%) were male. The median (range) follow-up was 43.2 (1-68) months. In the upfront surgery cohort (n\u2009=\u2009191), postsurgical MRD positivity was associated with worse DFS (hazard ratio [HR], 4.14; 95% CI, 2.69-6.36;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and OS (HR, 9.13; 95% CI, 4.44-18.78;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) compared with MRD negativity. Among patients with postsurgical MRD positivity, ACT was associated with improved DFS (HR, 0.07; 95% CI, 0.02-0.24;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; 48-month DFS: 37.5% [95% CI, 15.4-59.8] vs not reached) and OS (HR, 0.27; 95% CI, 0.08-0.88;\n P<\/jats:italic>\n \u2009=\u2009.03; 48-month OS: 65.3% [95% CI, 30.8-85.7] vs 32.9% [95% CI, 17.4-49.3]) compared with observation. In contrast, among patients with MRD negativity, ACT was not associated with improved DFS (HR, 0.69; 95% CI, 0.32-1.50;\n P<\/jats:italic>\n \u2009=\u2009.36) or OS (HR, 0.54; 95% CI, 0.10-2.88;\n P<\/jats:italic>\n \u2009=\u2009.47) benefit. In the NAC cohort (n\u2009=\u2009107), postsurgical MRD positivity remained prognostic, with inferior DFS (HR, 4.82; 95% CI, 2.92-7.97;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and OS (HR, 9.43; 95% CI, 2.78-31.96;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). ACT was not associated with improved DFS or OS regardless of MRD status. ctDNA positivity at the post-NAC presurgical time point was associated with worse OS (HR, 11.42; 95% CI, 1.58-1452.50;\n P<\/jats:italic>\n \u2009=\u2009.009).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this prognostic study, postsurgical ctDNA-defined MRD identified patients with resected CRLM who derived OS benefit from ACT. In contrast, patients with MRD negativity experienced favorable long-term OS without clear benefit from ACT. These findings support prospective validation of ctDNA-guided adjuvant strategies, particularly in patients with CRLM undergoing upfront surgery.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.2191","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:30:21Z","timestamp":1783092621000},"page":"950","source":"Crossref","is-referenced-by-count":2,"title":["Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases"],"prefix":"10.1001","volume":"12","author":[{"given":"Kozo","family":"Kataoka","sequence":"first","affiliation":[{"name":"Division of Lower GI Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Lower GI Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Oxford, Oxford, United Kingdom"},{"name":"Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Kansai Medical University, Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Sendai City Medical Center Sendai Open Hospital, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Kurashiki Central Hospital, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Surgery, Teine-Keijinkai Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kotaka","sequence":"additional","affiliation":[{"name":"Gastrointestinal Cancer Center, Sano Hospital, Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayoshi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan"},{"name":"Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Miyo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yukami","sequence":"additional","affiliation":[{"name":"Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkarachai","family":"Fungtammasan","sequence":"additional","affiliation":[{"name":"Natera, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Sharma","sequence":"additional","affiliation":[{"name":"Natera, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bryce","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Natera, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Rabinowitz","sequence":"additional","affiliation":[{"name":"Natera, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Lentz","sequence":"additional","affiliation":[{"name":"Natera, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham","family":"Jurdi","sequence":"additional","affiliation":[{"name":"Natera, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minetta C.","family":"Liu","sequence":"additional","affiliation":[{"name":"Natera, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Aleshin","sequence":"additional","affiliation":[{"name":"Natera, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Takemasa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Osaka International Medical and Science Center, Osaka Keisatsu Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Surgery, NHO Osaka National Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan"},{"name":"Department of Gastroenterological surgery\/Pediatric Surgery, Graduate School of Medicine, Gifu University, Gifu, Japan"},{"name":"Kindai University Faculty of Medicine, Higashiosaka City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CIRCULATE-Japan Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kimura","sequence":"additional","affiliation":[{"name":"for the CIRCULATE-Japan Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Matsuda","sequence":"additional","affiliation":[{"name":"for the CIRCULATE-Japan Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Ikeda","sequence":"additional","affiliation":[{"name":"for the CIRCULATE-Japan Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"for the CIRCULATE-Japan Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"for the CIRCULATE-Japan Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Sokuoka","sequence":"additional","affiliation":[{"name":"for the CIRCULATE-Japan Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"coi260032r1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ctrv.2015.06.006","article-title":"Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.","volume":"41","author":"Adam","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"coi260032r2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide.","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"issue":"1","key":"coi260032r3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/ags3.12227","article-title":"Multidisciplinary approach of liver metastases from colorectal cancer.","volume":"3","author":"Adam","year":"2019","journal-title":"Ann Gastroenterol Surg"},{"issue":"31","key":"coi260032r4","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2006.06.8353","article-title":"Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.","volume":"24","author":"Portier","year":"2006","journal-title":"J Clin Oncol"},{"issue":"30","key":"coi260032r5","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","article-title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.","volume":"26","author":"Mitry","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi260032r6","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/annonc\/mdp236","article-title":"A randomized phase III study comparing adjuvant 5-fluorouracil\/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.","volume":"20","author":"Ychou","year":"2009","journal-title":"Ann Oncol"},{"issue":"12","key":"coi260032r7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9","key":"coi260032r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162400","article-title":"Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: a randomized controlled trial.","volume":"11","author":"Hasegawa","year":"2016","journal-title":"PLoS One"},{"issue":"34","key":"coi260032r9","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1200\/JCO.21.01032","article-title":"Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for liver-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial.","volume":"39","author":"Kanemitsu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi260032r10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer.","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"coi260032r11","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","article-title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.","volume":"30","author":"Tarazona","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"coi260032r12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/gutjnl-2017-315852","article-title":"Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.","volume":"68","author":"Tie","year":"2019","journal-title":"Gut"},{"issue":"5","key":"coi260032r13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003620","article-title":"Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study.","volume":"18","author":"Tie","year":"2021","journal-title":"PLoS Med"},{"issue":"24","key":"coi260032r14","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"coi260032r15","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1158\/1078-0432.CCR-24-1651","article-title":"Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay.","volume":"30","author":"Nakamura","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"coi260032r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109706","article-title":"Prognostic role of postoperative persistence of ctDNA molecular signature after liver resection for colorectal liver metastases: preliminary results from a prospective study.","volume":"51","author":"Montalti","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"coi260032r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2026.01.006","article-title":"Circulating tumor DNA as a biomarker for recurrence after curative resection of colorectal cancer liver metastases: a systematic review and meta-analysis.","author":"Khan","year":"2026","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"coi260032r18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"coi260032r19","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer.","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"coi260032r20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2024.08.2240","article-title":"Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.","volume":"35","author":"Kataoka","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"coi260032r21","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1111\/cas.14926","article-title":"CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.","volume":"112","author":"Taniguchi","year":"2021","journal-title":"Cancer Sci"},{"issue":"3","key":"coi260032r22","doi-asserted-by":"publisher","first-page":"246","DOI":"10.23922\/jarc.2024-025","article-title":"Trial protocol of a phase II study of mFOLFOXIRI after metastasectomy in patients with oligometastatic colorectal cancer (FANTASTIC Study).","volume":"8","author":"Kataoka","year":"2024","journal-title":"J Anus Rectum Colon"},{"issue":"2","key":"coi260032r24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaoncol.2025.5144","article-title":"Predictive role of circulating tumor DNA in stage III colon cancer treated with celecoxib: a post hoc analysis of the CALGB (Alliance)\/SWOG 80702 phase 3 randomized clinical trial.","volume":"12","author":"Zhang","year":"2026","journal-title":"JAMA Oncol"},{"key":"coi260032r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.116092","article-title":"Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: an individual patient data meta-analysis.","volume":"231","author":"Bregni","year":"2025","journal-title":"Eur J Cancer"},{"issue":"4","key":"coi260032r26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/XCS.0000000000000093","article-title":"Effect of co-mutation of RAS and TP53 on postoperative ctDNA detection and early recurrence after hepatectomy for colorectal liver metastases.","volume":"234","author":"Nishioka","year":"2022","journal-title":"J Am Coll Surg"},{"key":"coi260032r27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1418696","article-title":"Feasibility of ctDNA in detecting minimal residual disease and predicting recurrence for colorectal cancer liver metastases.","volume":"14","author":"Kalil","year":"2024","journal-title":"Front Oncol"},{"issue":"7","key":"coi260032r28","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1097\/JS9.0000000000002504","article-title":"Dynamic CtDNA monitoring in adjuvant therapy and recurrence for colorectal liver metastases (PKUCRLM-01): a prospective study.","volume":"111","author":"Xu","year":"2025","journal-title":"Int J Surg"},{"issue":"10","key":"coi260032r29","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/S1470-2045(22)00506-X","article-title":"Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis.","volume":"23","author":"Ecker","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi260032r30","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/bjs\/znad127","article-title":"Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases.","volume":"110","author":"Kataoka","year":"2023","journal-title":"Br J Surg"},{"key":"coi260032r31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.breast.2020.01.006","article-title":"Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the \u201cATRESS\u201d phenomenon.","volume":"50","author":"Jurrius","year":"2020","journal-title":"Breast"},{"issue":"1","key":"coi260032r32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13073-026-01614-0","article-title":"Cancer evolution and multi-omic profile of relapsed colorectal liver metastases after treatment.","volume":"18","author":"Tom\u00e1s","year":"2026","journal-title":"Genome Med"},{"issue":"12","key":"coi260032r33","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","article-title":"Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial.","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"coi260032r34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.2026.44.2_suppl.153","article-title":"Adjuvant mFOLFOXFIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial.","volume":"44","author":"Kataoka","year":"2026","journal-title":"J Clin Oncol"},{"key":"coi260032r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2023.100034","article-title":"Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies.","volume":"3","author":"Oki","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"issue":"9","key":"coi260032r36","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1158\/1078-0432.CCR-20-3677","article-title":"Combined analysis of concordance between liquid and tumor tissue biopsies for RAS mutations in colorectal cancer with a single metastasis site: the METABEAM study.","volume":"27","author":"Kagawa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"coi260032r37","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00535","article-title":"Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer.","volume":"6","author":"Bando","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"coi260032r38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10147-024-02493-4","article-title":"Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.","volume":"29","author":"Hashimoto","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"coi260032r23","unstructured":"Fungtammasan? A. Kataoka-et-al_Upfront-and-NAC-Liver-Mets. Accessed January 30, 2026. https:\/\/github.com\/Natera-TMED\/Kataoka-et-al_Upfront-and-NAC-Liver-Mets"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2850973\/jamaoncology_kataoka_2026_oi_260032_1789560634.76522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:00:46Z","timestamp":1789657246000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2850973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.2191","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}